Tags

Type your tag names separated by a space and hit enter

Coenzyme Q10 improves contractility of dysfunctional myocardium in chronic heart failure.
Biofactors 2005; 25(1-4):137-45B

Abstract

BACKGROUND

There is evidence that plasma CoQ(10) levels decrease in patients with advanced chronic heart failure (CHF).

OBJECTIVE

To investigate whether oral CoQ(10) supplementation could improve cardiocirculatory efficiency in patients with CHF.

METHODS

We studied 21 patients in NYHA class II and III (18M, 3W, mean age 59 +/- 9 years) with stable CHF secondary to ischemic heart disease (ejection fraction 37 +/- 7%), using a double-blind, placebo-controlled cross-over design. Patients were assigned to oral CoQ(10) (100 mg tid) and to placebo for 4 weeks, respectively.

RESULTS

CoQ(10) supplementation resulted in a threefold increase in plasma CoQ(10) level (P < 0.0001 vs placebo). Systolic wall thickening score index (SWTI) was improved both at rest and peak dobutamine stress echo after CoQ(10) supplementation (+12.1 and 15.6%, respectively, P < 0.05 vs placebo). Left ventricular ejection fraction improved significantly also at peak dobutamine (15% from study entry P < 0.0001) in relation to a decrease in LV end-systolic volume index (from 57 +/- 7 mL/m(2) to 45 mL/m(2), P < 0.001). Improvement in the contractile response was more evident among initially akinetic (+33%) and hypokinetic (+25%) segments than dyskinetic ones (+6%). Improvement in SWTI was correlated with changes in plasma CoQ(10) levels (r = -0.52, P < 0.005). Peak VO(2) was also improved after CoQ(10) as compared with placebo (+13%, <0.005). No side effects were reported with CoQ(10).

CONCLUSIONS

Oral CoQ(10) improves LV contractility in CHF without any side effects. This improvement is associated with an enhanced functional capacity.

Authors+Show Affiliations

Lancisi Heart Institute, Department of Cardiology and Cardiac Surgery, Ancona, Italy. r.belardinelli@fastnet.itNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

16873938

Citation

Belardinelli, Romualdo, et al. "Coenzyme Q10 Improves Contractility of Dysfunctional Myocardium in Chronic Heart Failure." BioFactors (Oxford, England), vol. 25, no. 1-4, 2005, pp. 137-45.
Belardinelli R, Muçaj A, Lacalaprice F, et al. Coenzyme Q10 improves contractility of dysfunctional myocardium in chronic heart failure. Biofactors. 2005;25(1-4):137-45.
Belardinelli, R., Muçaj, A., Lacalaprice, F., Solenghi, M., Principi, F., Tiano, L., & Littarru, G. P. (2005). Coenzyme Q10 improves contractility of dysfunctional myocardium in chronic heart failure. BioFactors (Oxford, England), 25(1-4), pp. 137-45.
Belardinelli R, et al. Coenzyme Q10 Improves Contractility of Dysfunctional Myocardium in Chronic Heart Failure. Biofactors. 2005;25(1-4):137-45. PubMed PMID: 16873938.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Coenzyme Q10 improves contractility of dysfunctional myocardium in chronic heart failure. AU - Belardinelli,Romualdo, AU - Muçaj,Andi, AU - Lacalaprice,Francesca, AU - Solenghi,Maridia, AU - Principi,Federica, AU - Tiano,Luca, AU - Littarru,Gian Paolo, PY - 2006/7/29/pubmed PY - 2006/10/7/medline PY - 2006/7/29/entrez SP - 137 EP - 45 JF - BioFactors (Oxford, England) JO - Biofactors VL - 25 IS - 1-4 N2 - BACKGROUND: There is evidence that plasma CoQ(10) levels decrease in patients with advanced chronic heart failure (CHF). OBJECTIVE: To investigate whether oral CoQ(10) supplementation could improve cardiocirculatory efficiency in patients with CHF. METHODS: We studied 21 patients in NYHA class II and III (18M, 3W, mean age 59 +/- 9 years) with stable CHF secondary to ischemic heart disease (ejection fraction 37 +/- 7%), using a double-blind, placebo-controlled cross-over design. Patients were assigned to oral CoQ(10) (100 mg tid) and to placebo for 4 weeks, respectively. RESULTS: CoQ(10) supplementation resulted in a threefold increase in plasma CoQ(10) level (P < 0.0001 vs placebo). Systolic wall thickening score index (SWTI) was improved both at rest and peak dobutamine stress echo after CoQ(10) supplementation (+12.1 and 15.6%, respectively, P < 0.05 vs placebo). Left ventricular ejection fraction improved significantly also at peak dobutamine (15% from study entry P < 0.0001) in relation to a decrease in LV end-systolic volume index (from 57 +/- 7 mL/m(2) to 45 mL/m(2), P < 0.001). Improvement in the contractile response was more evident among initially akinetic (+33%) and hypokinetic (+25%) segments than dyskinetic ones (+6%). Improvement in SWTI was correlated with changes in plasma CoQ(10) levels (r = -0.52, P < 0.005). Peak VO(2) was also improved after CoQ(10) as compared with placebo (+13%, <0.005). No side effects were reported with CoQ(10). CONCLUSIONS: Oral CoQ(10) improves LV contractility in CHF without any side effects. This improvement is associated with an enhanced functional capacity. SN - 0951-6433 UR - https://www.unboundmedicine.com/medline/citation/16873938/Coenzyme_Q10_improves_contractility_of_dysfunctional_myocardium_in_chronic_heart_failure_ L2 - https://content.iospress.com/openurl?genre=article&amp;issn=0951-6433&amp;volume=25&amp;issue=1-4&amp;spage=137 DB - PRIME DP - Unbound Medicine ER -